Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Now Viewing

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Ultra-Low PSA Responses and Clinical Outcomes

Key Themes:

• Correlation between achieving PSA <0.02 ng/mL and clinical outcomes
• Impact on time to progression and radiographic progression-free survival (rPFS)
• Overall survival trends in relation to PSA response

Expert Insights:

• Dr Shore presented data demonstrating that patients achieving ultra-low PSA levels (<0.02 ng/mL) experienced improved clinical outcomes.

The analysis showed correlations between ultra-low PSA and important end points including time to progression, rPFS, and overall survival trends